Sigyn Therapeutics, Inc. (OTCQB: SIGY) disclosed today that a recent study reported by Scientific American and published in Science Translational Medicine provides clinical evidence of blood-brain barrier disruption in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE), a condition commonly diagnosed post-mortem in former NFL players. The findings, which indicate that the blood-brain barrier may remain compromised for decades after an athlete's retirement, underscore the potential of Sigyn's CardioDialysis technology to treat neuroinflammatory diseases.
On March 21, Scientific American published an article titled "Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports" coinciding with a study in Science Translational Medicine. Researchers at Trinity College Dublin reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having CTE. When the blood-brain barrier is compromised, inflammatory molecules and pathogenic toxins from the bloodstream can enter the brain, triggering neuroinflammation and abnormal tau protein accumulation, a hallmark of CTE. The former athletes studied appeared to exist in a persistent state of chronic hyperinflammation.
This study adds to growing evidence that systemic inflammation drives neuroinflammation in disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. CardioDialysis, a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules, is uniquely positioned as a potential adjunct therapy for these conditions. Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI), while its lead clinical indication remains cardiovascular disease, the leading cause of death worldwide.
"It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease," stated Sigyn Therapeutics CEO Jim Joyce. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain."
CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. In cardiovascular disease, it aims to reduce inflammatory mediators and lower cholesterol-transporting lipoproteins. Its broad-spectrum mechanism also makes it a candidate for sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation. Sigyn's development pipeline includes ImmunePrep, ChemoPrep, and ChemoPure to enhance cancer therapies. For more information, visit SigynTherapeutics.com.
